VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since ... are expected in Q4'23. Vir Biotechnology (NASDAQ:VIR) is a biotech ...

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and ...

NEW YORK (CBS.MW) - Biotechnology stocks ebbed lower Wednesday, with shares of Celgene Corp. among the leading decliners after an analyst cut his rating on the company's stock. The Amex ...

The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.

This article was originally published on ETFTrends.com. Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit ...